Compare BXSL & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | APGE |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2018 | 2023 |
| Metric | BXSL | APGE |
|---|---|---|
| Price | $23.43 | $133.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $27.18 | ★ $109.67 |
| AVG Volume (30 Days) | 1.9M | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 12.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $210.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.47 | $34.34 |
| 52 Week High | $32.81 | $133.87 |
| Indicator | BXSL | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 81.20 |
| Support Level | $23.26 | $73.70 |
| Resistance Level | $24.93 | N/A |
| Average True Range (ATR) | 0.46 | 0.44 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 32.51 | 78.87 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.